NDA 219407 · Ionis Pharms INC
Dawnzera (Autoinjector)
Donidalorsen Sodium · Subcutaneous
NovelOrphanCDER novel approval, Aug 21, 2025: To prevent attacks of hereditary angioedema
Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 21, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 1 recruiting
FAERS reports
506
55 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
DAWNZERA™ is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is a prekallikrein directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. ( 1 )
Mechanism: Donidalorsen is an ASO‑GalNAc conjugate that causes ribonuclease H1 (RNase H1)‑mediated degradation of PKK mRNA through binding to PKK mRNA, which results in reduced production of PKK protein. PKK is a pro‑enzyme for plasma kallikrein, which results in the release of bradykinin, a potent vasodilator causing swelling and pain in HAE. In patients with HAE, C1‑inhibitor (C1‑INH) deficiency or dysfunction leads to excessive plasma kallikrein activity, bradykinin generation, and angioedema attacks. Donidalorsen lowers PKK concentration, preventing excessive bradykinin production in patients with...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DAWNZERA (AUTOINJECTOR) · DONIDALORSEN SODIUM EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Donidalorsen" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)Pivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05392114 · 154 participants · Start Jul 13, 2022 · Primary completion Dec 2026
Drug: Donidalorsen · For: Hereditary Angioedema
Sites: Paradise Valley, Arizona; La Jolla, California; Santa Monica, California · 50 sites in all
- OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)Pivotal-lookingCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05139810 · 91 participants · Start Dec 3, 2021 · Primary completion Nov 9, 2023
Drug: Donidalorsen; Placebo · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; San Diego, California; Santa Monica, California · 51 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT03263507 · 32 participants · Start Aug 28, 2017 · Primary completion Oct 9, 2018
Drug: Placebo; Donidalorsen · For: Healthy Volunteers
Sites: Toronto, Canada
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04030598 · 23 participants · Start Jan 7, 2020 · Primary completion Jan 4, 2021
Drug: Donidalorsen; Placebo · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; San Diego, California; Santa Monica, California · 8 sites in all
- Donidalorsen Treatment in Children With Hereditary AngioedemaPivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07298447 · 20 participants (planned) · Start Apr 21, 2026 · Primary completion Jun 2029
Drug: Donidalorsen · For: Hereditary Angioedema (HAE)
Sites: Santa Monica, California; Miami, Florida; Baton Rouge, Louisiana · 18 sites in all
- An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaCompleted
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04307381 · 20 participants · Start Mar 31, 2020 · Primary completion Jan 24, 2025
Drug: Donidalorsen · For: Hereditary Angioedema
Sites: Scottsdale, Arizona; Santa Monica, California; Plymouth, Minnesota · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema215
- injection site pain41
- headache31
- injection site erythema27
- injection site bruising20
- nausea19
- abdominal distension18
- fatigue18
- dizziness17
- peripheral swelling17
- abdominal pain15
- malaise13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 5 |
| 2026 | 501 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
Riedl MA, Tachdjian R, Lumry WR, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Inhibition of Prekallikrein for Hereditary Angioedema.
Fijen LM, Riedl MA, Bordone L, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Multicenter Study
- Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.
Riedl MA, Bernstein JA, Jacobs JS, et al. · J Allergy Clin Immunol Pract 2025 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of Donidalorsen in Hereditary Angioedema with C1 inhibitor deficiency: a systematic review and a meta analysis.
Raja A, Shuja MH, Raja S, et al. · Arch Dermatol Res 2024 · Meta-Analysis, Systematic Review
- Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema.
Singh P, Witjes H, Kleijn HJ, et al. · Clin Transl Sci 2025 · Clinical Trial, Phase III, Multicenter Study
- A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
Petersen RS, Bordone L, Riedl MA, et al. · Allergy 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Ionis Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.